Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report?
Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Best Value Stocks to Buy for Jan.14
GES, NESR and ALKS made it to the Zacks Rank #1 (Strong Buy) value stocks list on Jan.14, 2026.
Alkermes: Avadel Deal And Vibrance-2 Unlock Upside
Alkermes is transforming into a fully integrated biopharma, leveraging Vibrance-2 results and the Avadel acquisition for competitive advantage in sleep medicine. ALKS's robust legacy portfolio funds rapid R&D expansion, with Lybalvi sales up 32% and strong gross-to-net dynamics supporting operational profitability. Alixorexton's Phase 2 success in both narcolepsy types and idiopathic hypersomnia, plus a clean safety profile, significantly de-risk the clinical pipeline.
FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug
Alkermes wins FDA Breakthrough Therapy status for alixorexton in NT1 after Vibrance-1 data shows improvement in wakefulness.
Are Investors Undervaluing Alkermes (ALKS) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Alkermes plc (ALKS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Alkermes plc (ALKS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Why Is Alkermes (ALKS) Down 5.5% Since Last Earnings Report?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal
Alkermes lifts its bid to buy Avadel for $22.50 per share as its takeover fight with Lundbeck intensifies and shifts the deal's momentum.
Alkermes raises offer for Avadel after Lundbeck bid
Alkermes said on Wednesday it has sweetened its offer to buy Avadel Pharmaceuticals , beating a rival bid from Denmark's Lundbeck and valuing the sleep disorder drugmaker at up to $2.37 billion.
Alkermes plc (ALKS) Shareholder/Analyst Call Transcript
Alkermes plc ( ALKS ) Shareholder/Analyst Call November 12, 2025 8:30 AM EST Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Richard F. Pops - Chairman & CEO Craig Hopkinson - Executive VP of Research & Development and Chief Medical Officer Conference Call Participants Joon Lee - Truist Securities, Inc., Research Division Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Luke Herrmann - Robert W.
H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal
The unsolicited bid—worth up to $2.25 billion —potentially upends Avadel's deal to be acquired by Alkermes.
Alkermes reviewing options after Lundbeck makes unsolicited bid for Avadel
Alkermes said on Friday it is reviewing its options with advisers after Avadel Pharmaceuticals disclosed it had received an unsolicited takeover proposal from Danish pharmaceutical company Lundbeck.
